Thursday, January 16, 2025

Character Biosciences, Bausch + Lomb Collaborate to Develop Treatments for Patients with AMD

The partnership will initially focus on AMD, with the potential to expand into other eye conditions.

Thursday, January 16, 2025

Los Angeles County Wildfires Prompt SBA to Open Local Business Recovery Centers

Attention private practice owners: The U.S. Small Business Administration (SBA) has opened two Business Recovery Centers (BRC) in Los Angeles County to help.

Wednesday, January 15, 2025

GenSight Biologics Publishes 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ

Five years after the one-time injection, patients with Leber hereditary optic neuropathy due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and a favorable safety profile. 

Wednesday, January 15, 2025

Inflammasome Therapeutics Reports Topline 3-month Data from a Clinical Trial of First-in-Class Dual Inflammasome Inhibitor in GA

In a US clinical trial of five patients with bilateral geographic atrophy, sustained-release intravitreous implants of K8 were well tolerated, with no drug-related ocular or systemic serious adverse events.

Wednesday, January 15, 2025

Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with TED

The LIDS trial met its primary endpoint with statistical significance for the 150 mg BID dose.

Tuesday, January 14, 2025

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Trial in DME

The 3E10 vg/eye dose demonstrated notable efficacy, achieving sustained visual acuity gains.

Tuesday, January 14, 2025

HelpMeSee Expands Simulation-based Cataract Surgery Training with New Partnerships at USC, UIC

These collaborations establish two new simulation-based surgical training locations to advance ophthalmic education while also addressing the global cataract blindness crisis.

Tuesday, January 14, 2025

Bausch + Lomb, GRF Launch Second Annual ‘Faces of Glaucoma’ Campaign and Fundraising Challenge

Throughout January, Bausch + Lomb and Glaucoma Research Foundation will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease.

Tuesday, January 14, 2025

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for GA

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Tuesday, January 14, 2025

Alkeus Reports Positive Interim Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

The data demonstrated that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years.

Tuesday, January 14, 2025

Samsara Reports Positive 6-Month Visual and Safety Outcomes from the SING IMT

The study showed that the percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months.

Monday, January 13, 2025

Bausch + Lomb Acquires Whitecap Biosciences

With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Biosciences strengthens B + L’s expanding clinical-stage pipeline. 

Monday, January 13, 2025

Zeiss's MEL 90 Excimer Laser Wins FDA Approval

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE and completes Corneal Refractive Workflow, company says.

Friday, January 10, 2025

Tenpoint Reports Positive Data from BRIO-II Phase 3 Pivotal Study of BRIMOCHOL PF for Presbyopia

Tenpoint Therapeutics' BRIMOCHOL PF successfully met the pre-specified visual acuity primary endpoints for both the United States and EU/UK with highly statistically significant near- vision improvements over 8 hours.

Thursday, January 9, 2025

FDA Clears Epithelial Thickness Module for Heidelberg Engineering’s Anterion Multidisciplinary Imaging Platform

The module equips eye-care professionals with advanced thickness mapping and data insights to evaluate both the epithelial and stromal structures.

Thursday, January 9, 2025

FDA Confirms Class 1 Resubmission of the Supplemental NDA for IZERVAY for Geographic Atrophy

The supplemental new drug application seeks to add positive 2-year data to the IZERVAY U.S. Prescribing Information based on results from the GATHER2 Phase 3 clinical trial.

Thursday, January 9, 2025

Rayner Launches Redesigned Online Premium IOL Calculator, Raytrace

The newly-redesigned RayTrace version 4.0 reflects surgeon feedback with quicker and clearer calculations, access to the PEARL DGS formula, and a host of other new features.

Wednesday, January 8, 2025

Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients

The research team demonstrated the effectiveness of their technique in multiple models, including human tissues. 

Tuesday, January 7, 2025

Sozinibercept Shows Efficacy as Diabetic Macular Edema Treatment

Recently published results of a Phase 1 study support its potential in combination with aflibercept.

Tuesday, January 7, 2025

Canyon Labs to Acquire iuvo BioScience's Labs Services and Consulting Business

The strategic acquisition enables Canyon to expand its end-to-end development solutions and strengthens both organizations' market positions.

Tuesday, January 7, 2025

Regeneron Acquires Biotech Firm Oxular

The acquisition will strengthen Regeneron Pharmaceuticals' gene therapy development program.

Tuesday, January 7, 2025

Cencora Finalizes Retina Consultants of America Acquisition

The acquisition aims to strengthen Cencora’s position in the specialty health-care market and expand its management services organization offerings.

Tuesday, January 7, 2025

Soliddd Introduces Smartglasses Technology at CES 2025

SolidddVision’s vision correction technology can improve sight for patients with macular degeneration and other conditions.

Tuesday, January 7, 2025

EssilorLuxottica Announces Agreement to Acquire Espansione Group

EssilorLuxottica aims to leverage Espansione’s technology to advance its mission of improving vision health.

Tuesday, January 7, 2025

Galimedix Initiates Trial for Dry AMD Eyedrops

The Phase 2 study will examine GAL-101’s potential to slow the growth of geographic atrophy lesions.

Monday, January 6, 2025

Oculis Phase 2 ACUITY Trial in Acute Optic Neuritis Meets Primary Safety Endpoint, Key Secondary Efficacy Endpoints

Oculis' OCS-05 showed a favorable safety and tolerability profile compared to placebo, and achieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective structural measures of retinal thickness and visual improvement. 

Friday, January 3, 2025

Prevent Blindness Offers Free Resources for National Glaucoma Awareness Month

In an effort to support National Glaucoma Awareness Month in January, Prevent Blindness is providing patients, care partners and professionals with free educational resources.

Thursday, January 2, 2025

Valo Health Suspends Development of Diabetic Retinopathy Drug

While the Phase 2 SPEC­TRA study did not meet its pri­ma­ry or sec­ondary end­points based on the analy­sis in the pre­de­fined pri­ma­ry pop­u­la­tion, cer­tain dos­es test­ed in the study showed poten­tial evi­dence of pre­vent­ing dis­ease pro­gres­sion.

Thursday, January 2, 2025

Mandatory Patient Experience Evaluating Reporting (OHS CAHPS) Begins Now

New year, new requirements: OOSS warns ACS that do not administer and report OHS CAHPS in 2025 could be subject to a penalty of 2% of their annual Medicare payment update.